Study of JY231 injection for tough nerve immune disorders
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have one of these immune disorders: neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, myositis, multiple sclerosis, autoimmune encephalitis, or MOG antibody disease.
- You have tried standard treatments (like steroids, immune-suppressing drugs, or plasma exchange) and they didn't work well, or you couldn't tolerate them.
- Your disease is still active—meaning you've had recent relapses or symptoms that interfere with daily life.
- Your heart, lungs, kidneys, and liver are working fairly well, and you are able to do most daily activities with little help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
This trial tests an experimental treatment called JY231 for people with certain autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, dermatomyositis, or vasculitis that haven't improved with standard treatments. The goal is to see if JY231 can help control the disease when other options haven't worked.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This trial tests a new cell-based treatment (called HY001N) for people with certain autoimmune neurological diseases that have not responded to standard treatments. The treatment aims to reset the immune system to reduce attacks and improve symptoms.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
Hear when a new Autoimmune Diseases of the Nervous System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.